E-ISSN 2602-3164
EJMI. 2022; 6(1): 33-37 | DOI: 10.14744/ejmi.2022.53326

Could Pretreatment Neutrophil/Lymphosit Ratio and Derived Neutrophil/Lymphosit Ratio Predict Overall Survival of Patients With Extensive Stage Small Cell Lung Cancer?

Aykut Bahceci1, Ayse Kotek Sedef2
1Department of Medical Oncology, Dr. Ersin Arslan Education and Research Hospital, Gaziantep, Turkey, 2Department of Radiation Oncology, Dr. Ersin Arslan Education and Research Hospital, Gaziantep, Turkey

Objectives: We designed this study to evaluate the prognostic significance of basal neutrophil / lymphocyte ratio (NLR), derived NLR (dNLR) and systemic immune inflammation index (SII) in patients with extensive stage (ES) SCLC treated with platinum-based combination regimen. Methods: This study was a hospital-based retrospective observational case-series study. 145 ES SCLC patients were included the study from Dr. Ersin Arslan Education and Research Hospital Departments of Medical Oncology and Radiation Oncology between the years of 2011-2018. Results: The median age of the patients was 61 (range 31-81) years and 131 (90.3%) patients were male. 144 (99,3 %) patients were treated with the platinum etoposide combination regimen and 134 patients (92,4 %) received cisplatin in combination. The median follow-up time was 10 months and 116 (80%) patients died. Progression-free survival (PFS) and overall survival (OS) were estimated, respectively, as 8 and 12 months. Patients in the low NLR and low dNLR scores had better overall survival than those with high NLR and high dNLR (14 versus 10 months respectively and p=0,01). Conclusion: This study showed that basal NLR and dNLR may have prognostic biological value in patients with ES SCLC treated with cisplatin + etoposide. Keywords: Derived neutrophil/lymphosit ratio, extensive stage, neutrophil/lymphosit ratio, overall survival, small cell lung cancer.


Cite This Article

Bahceci A, Sedef A. Could Pretreatment Neutrophil/Lymphosit Ratio and Derived Neutrophil/Lymphosit Ratio Predict Overall Survival of Patients With Extensive Stage Small Cell Lung Cancer?. EJMI. 2022; 6(1): 33-37

Corresponding Author: Aykut Bahceci

Full Text PDF PDF Download
EJMI & EJMI